Your browser doesn't support javascript.
loading
An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy.
Janes, Peter W; Parslow, Adam C; Cao, Diana; Rigopoulos, Angela; Lee, Fook-Thean; Gong, Sylvia J; Cartwright, Glenn A; Burvenich, Ingrid J G; Eriksson, Ulf; Johns, Terrance G; Scott, Fiona E; Scott, Andrew M.
Afiliación
  • Janes PW; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • Parslow AC; School of Cancer Medicine, La Trobe University, Melbourne, VIC 3083, Australia.
  • Cao D; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • Rigopoulos A; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • Lee FT; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • Gong SJ; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • Cartwright GA; School of Computing, Engineering and Mathematical Sciences, La Trobe University, Melbourne, VIC 3083, Australia.
  • Burvenich IJG; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC 3084, Australia.
  • Eriksson U; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • Johns TG; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
  • Scott FE; School of Cancer Medicine, La Trobe University, Melbourne, VIC 3083, Australia.
  • Scott AM; Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, 171 77 Solna, Sweden.
Cancers (Basel) ; 16(10)2024 May 16.
Article en En | MEDLINE | ID: mdl-38791979
ABSTRACT
The vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) are key regulators of blood vessel formation, including in tumors, where their deregulated function can promote the production of aberrant, leaky blood vessels, supporting tumor development. Here we investigated the VEGFR1 ligand VEGF-B, which we demonstrate to be expressed in tumor cells and in tumor stroma and vasculature across a range of tumor types. We examined the anti-VEGF-B-specific monoclonal antibody 2H10 in preclinical xenograft models of breast and colorectal cancer, in comparison with the anti-VEGF-A antibody bevacizumab. Similar to bevacizumab, 2H10 therapy was associated with changes in tumor blood vessels and intra-tumoral diffusion consistent with normalization of the tumor vasculature. Accordingly, treatment resulted in partial inhibition of tumor growth, and significantly improved the response to chemotherapy. Our studies indicate the importance of VEGF-B in tumor growth, and the potential of specific anti-VEGF-B treatment to inhibit tumor development, alone or in combination with established chemotherapies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Suiza